Between-centre differences for COVID-19 ICU mortality from early data in England

Zhaozhi Qian[1], Ahmed M. Alaa[2], Mihaela van der Schaar[1], and Ari Ercole[3,*]

[1]University of Cambridge Centre for Mathematical Sciences, Wilberforce Rd, Cambridge CB3 0WA, UK
[2]University of California, Los Angeles, CA 90095, USA
[3]University of Cambridge Division of Anaesthesia, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK
[*]Correspondence: ae105@cam.ac.uk

The high numbers of COVID-19 patients developing severe respiratory failure has placed exceptional demands on ICU capacity around the world. Understanding the determinants of ICU mortality is important for surge planning and shared decision making. We used early data from the COVID-19 Hospitalisation in England Surveillance System (from the start of data collection 8th February -14th April 2020) to look for factors associated with ICU outcome in the hope that information from such timely analysis may be actionable before the outbreak peak. Immunosuppression, chronic heart/renal disease and age were key determinants of ICU mortality in a proportional hazards mixed effects model. However variation in site-stratified random effects were even comparable in magniture suggesting substantial between-centre variability in mortality. Notwithstanding possible ascertainment and lead-time effects, these early results motivate comparative effectiveness research to understand the origin of such differences and optimise surge ICU provision.

Introduction

Since the first cases emerged in November 2019 [1], the spread of SARS-CoV-2 infections has placed an unprecedented strain on healthcare resources globally. The intensive care unit (ICU) is a setting of particular concern as high numbers of patients developing severe respiratory complications from COVID-19 means that advanced outcome-critical resources may be rapidly exhausted. Indeed, in some areas, ICUs have been completely overwhelmed [2].

Understanding the determinants of ICU outcome is crucial both for surge planning and shared decision making with patients and relatives. Whilst a number of risk scores have been published [3] they do not specifically look at this population. Furthermore, ICU availability, admission policy and structure varies substantially across Europe [4] as do population demographics and government policy for surveillance and containment. As a result, it is likely that ICU outcomes could vary significantly from region to region which motivates an individualised approach to modelling. UK mortality has been particularly high and we sought to identify predictors of mortality in patients admitted to the ICU with COVID-19.

Data and analysis

We obtained de-identified COVID-19 Hospitalisation in England Surveillance System (CHESS) data from Public Health England (PHE) for the period from 8th February (data collection start) to 14th April 2020 (3,092 cases ICU cases– 609 deaths, 384 discharges from 94 NHS trusts across England). Mean APACHE-II score for each site from ICU national audit data for COVID-19 patients over a similar period was used to attempt to correct for case-severity/as a proxy for admission policy.

We used a Cox proportional hazards mixed-effects model for mortality, with the NHS trust as the random effect. The estimated coefficients associated with each predictor are shown in Figure 1. The proportional hazards assumption was not significantly violated ($p = 0.11$).

Discussion and conclusions

Immunosuppression, chronic heart/renal disease and age were key predictors of mortality. In comparison with these fixed effects, the magnitude of the between-centre variation (hazard ratio between 0 to +4) is comparable to the strongest fixed effects predictor. The cause of such between-centre variation is unclear and may have a variety of residual case-mix or structural explanations. In particular, ICU demand varies both regionally and locally and we may hypothesize that high levels of strain or constraints on surge capacity could be actionable determinants, although we do not have data to examine this. Such considerations are important to understand as they may influence optimal configuration or transfer considerations locally.

Figure 1: **Panel (A)** *Figure 1: Panel (A) Fixed effects estimates for CHESS predictors and mean APACHE-II score for each site from national audit data. The strongest patient-factor predictors are older age, immunosuppressive disease and chronic heart / renal disease. The inset shows mortality probability over time for young, intermediate and older age groups.* **Panel (B)** *random effects showing between centres variation showing a hazard ratio variation between sites from 0 to over +4 which is comparable in magnitude to the strongest CHESS predictor (older age) showing that between-centres variation is an appreciable determinant of outcome. 95% CIs shown.*

In an attempt to create an analysis on an actionable timescale, we use early data which inevitably suffers from incomplete ascertainment, particularly before approximately 15th March. Furthermore, the earlier deaths in the elderly group may result in some lead time bias due to censoring (although an additional analysis was performed excluding patients with < 7 days follow-up and yielded qualitatively similar results) and we cannot track outcomes on patients who are transferred. Nevertheless, the magnitude of the random effects is striking. This motivates urgent comparative effectiveness research to better characterise between-centre differences in outcome which may inform best practice in surge situations both in England and elsewhere.

Acknowledgements

We would like to acknowledge Public Health England for providing us access to the CHESS dataset and the intensive care national audit and research centre for providing aggregate APACHE-II data. In particular, we would like to acknowledge Anees Pari and Geraldine Linehan for their support.

Availability of data and materials statement

Source data controlled by Public Health England. Under the terms of our data sharing agreement, the authors are not able to re-share the source data but will entertain requests for scientific collaboration.

Competing interests

None to declare.

Funding

Not externally funded.

Authors' contributions

AE and MvdS conceived of and supervised the study. ZQ and AMA coded the statistical models. All authors contributed to the manuscript.

References

[1] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, Xu W, Zhang C, Yu J, Jiang B, Cao H, and Li L (2020). Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis doi:10.1093/cid/ciaa199.

[2] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, and Pesenti A (2020). Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA doi:10.1001/jama.2020.5394.

[3] Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, Haller MC, Heinze G, Moons KGM, Riley RD, Schuit E, Smits LJM, Snell KIE, Steyerberg EW, Wallisch C, and van Smeden M (2020). Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 369:m1328.

[4] Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, and Moreno RP (2012). The variability of critical care bed numbers in Europe. Intensive Care Med 38:1647–1653.